XML 42 R5.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 6 Months Ended
Sep. 28, 2013
Sep. 29, 2012
Cash Flows from Operating Activities:    
Net income $ 8,674 $ 16,335
Non-cash items:    
Depreciation and amortization 38,256 28,610
Amortization of financing costs 815 0
Stock compensation expense 6,416 5,014
Purchase of in-process R&D 3,569 0
Loss on sale of property, plant and equipment 265 218
Unrealized loss from hedging activities 2,266 166
Interest expense on contingent consideration 310 0
Asset write-down 1,675 0
Change in operating assets and liabilities:    
Decrease/(increase) in accounts receivable, net 8,689 (22,686)
Increase in inventories (19,338) (3,448)
Increase in prepaid income taxes (1,459) (2,197)
Decrease/(increase) in other assets and other liabilities 5,067 (4,337)
Tax benefit of exercise of stock options 1,338 2,488
(Increase)/decrease in accounts payable and accrued expenses (13,781) 13,404
Net cash provided by operating activities 42,762 33,567
Cash Flows from Investing Activities:    
Capital expenditures on property, plant and equipment (28,202) (34,432)
Proceeds from sale of property, plant and equipment 642 355
Acquisition of Hemerus 0 (535,144)
Acquisition of Hemerus (23,124) (1,000)
Other acquisitions and investments (8,707) 0
Net cash used in investing activities (59,391) (570,221)
Cash Flows from Financing Activities:    
Payments on long-term real estate mortgage (472) (434)
Net increase in short-term loans 4,240 3,217
Term loan borrowing 0 475,000
Repayment of term loan borrowings (20,000) 0
Debt issuance costs 0 (5,462)
Proceeds from employee stock purchase plan 2,666 2,105
Proceeds from exercise of stock options 8,117 23,649
Excess tax benefit on exercise of stock options 1,581 2,079
Share repurchase 0 (5,342)
Net cash (used in)/provided by financing activities (3,868) 494,812
Effect of exchange rates on cash and cash equivalents 525 32
Net Decrease in Cash and Cash Equivalents (19,972) (41,810)
Cash and Cash Equivalents at Beginning of Period   228,861
Cash and Cash Equivalents at End of Period 159,148 187,051
Non-cash Investing and Financing Activities:    
Transfers from inventory to fixed assets for placements of Haemonetics equipment 6,034 11,167
Supplemental Disclosures of Cash Flow Information:    
Interest paid 4,722 1,688
Income taxes paid $ 3,666 $ 7,338